CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice.Material and methods. The study included 103 patients with ACS without indications for long-term anticoagulant therapy, which...

Full description

Bibliographic Details
Main Authors: A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2017-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
acute coronary syndrome
pharmacogenetics
cyp2c19
clopidogrel
ticagrelor
clinical guidelines
Online Access:https://www.rpcardio.com/jour/article/view/1564

Internet

https://www.rpcardio.com/jour/article/view/1564

Similar Items